Monthly Archives: January 2023

New-onset Parkinsonism as a Covid-19 infection sequela: A systematic review and meta-analysis Posted on January 30, 2023 by admin

Highlights There have been well-documented reports about the occurrence of parkinsonism after viral infections. 10 studies including 13 patients reported the development of parkinsonism in individuals who recovered from COVID-19 infection. The commonest symptom of parkinsonism reported in these individuals … Continue reading →

Posted in Uncategorized | Comments Off on New-onset Parkinsonism as a Covid-19 infection sequela: A systematic review and meta-analysis
Neuroinflammation is independently associated with brain network dysfunction in Alzheimer’s disease Posted on January 29, 2023 by admin

Abstract: Brain network dysfunction is increasingly recognised in Alzheimer’s disease (AD). However, the causes of brain connectivity disruption are still poorly understood. Recently, neuroinflammation has been identified as an important factor in AD pathogenesis. Microglia participate in the construction and … Continue reading →

Posted in Uncategorized | Comments Off on Neuroinflammation is independently associated with brain network dysfunction in Alzheimer’s disease
Virus exposure and neurodegenerative disease risk across national biobanks Posted on January 27, 2023 by admin

Highlights • Identified 45 pairs of viral exposures associated with increased risk of NDDs • Replicated 22 of the viral exposures/NDD pairings • Replicated the previously reported Epstein-Barr and multiple sclerosis association • Follow-up shows significantly elevated risk of NDD … Continue reading →

Posted in Uncategorized | Comments Off on Virus exposure and neurodegenerative disease risk across national biobanks
Interactions between SARS-CoV-2 N-Protein and α-Synuclein Accelerate Amyloid Formation Posted on January 21, 2023 by admin

Semerdzhiev SA, Fakhree MAA, Segers-Nolten I, Blum C, Claessens MMAE. Interactions between SARS-CoV-2 N-Protein and α-Synuclein Accelerate Amyloid Formation. ACS Chem Neurosci. 2022 Jan 5;13(1):143-150. doi: 10.1021/acschemneuro.1c00666. Epub 2021 Dec 3. PMID: 34860005; PMCID: PMC8739828. https://pubmed.ncbi.nlm.nih.gov/34860005/

Posted in Uncategorized | Comments Off on Interactions between SARS-CoV-2 N-Protein and α-Synuclein Accelerate Amyloid Formation
Investigating neurological symptoms of infectious diseases like COVID-19 leading to a deeper understanding of neurodegenerative disorders such as Parkinson’s disease Posted on January 15, 2023 by admin

Abstract: “Apart from common respiratory symptoms, neurological symptoms are prevalent among patients with COVID-19. Research has shown that infection with SARS-CoV-2 accelerated alpha-synuclein aggregation, induced Lewy-body-like pathology, caused dopaminergic neuron senescence, and worsened symptoms in patients with Parkinson’s disease (PD). … Continue reading →

Posted in Uncategorized | Comments Off on Investigating neurological symptoms of infectious diseases like COVID-19 leading to a deeper understanding of neurodegenerative disorders such as Parkinson’s disease
Early-Onset Parkinson’s Disease: Creating the Right Environment for a Genetic Disorder Posted on January 15, 2023 by admin

Abstract: “Parkinson’s disease (PD) by its common understanding is a late-onset sporadic movement disorder. However, there is a need to recognize not only the fact that PD pathogenesis expands beyond (or perhaps to) the brain but also that many early-onset … Continue reading →

Posted in Uncategorized | Comments Off on Early-Onset Parkinson’s Disease: Creating the Right Environment for a Genetic Disorder
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 Posted on January 13, 2023 by admin

Abstract:  Importance  The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown. Objective  To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes. Design, Setting, and Participants  Prespecified … Continue reading →

Posted in Uncategorized | Comments Off on Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19
Estimated Global Proportions of Individuals With Persistent Symptoms Following Symptomatic COVID-19 Posted on January 10, 2023 by admin

Abstract:   Importance  Some individuals experience persistent symptoms after initial symptomatic SARS-CoV-2 infection (often referred to as Long COVID). Objective  To estimate the proportion of males and females with COVID-19, younger or older than 20 years of age, who had … Continue reading →

Posted in Uncategorized | Comments Off on Estimated Global Proportions of Individuals With Persistent Symptoms Following Symptomatic COVID-19
Huntington disease oligodendrocyte maturation deficits are rescued by thiamine-biotin supplementation Posted on January 5, 2023 by admin

Lim, R.G., Al-Dalahmah, O., Wu, J. et al. Huntington disease oligodendrocyte maturation deficits revealed by single-nucleus RNAseq are rescued by thiamine-biotin supplementation. Nat Commun 13, 7791 (2022). https://doi.org/10.1038/s41467-022-35388-x https://www.nature.com/articles/s41467-022-35388-x

Posted in Uncategorized | Comments Off on Huntington disease oligodendrocyte maturation deficits are rescued by thiamine-biotin supplementation
Molecular Bases of Serotonin Reuptake Inhibitor Antidepressant-Attributed Effects in COVID-19 Posted on January 1, 2023 by admin

Abstract: “Widely available effective drugs to treat coronavirus disease-2019 (COVID-19) are still limited. Various studies suggested the potential contribution of selective serotonin-reuptake inhibitor (SSRI) antidepressants to alleviate the clinical course of COVID-19. Initially, SSRI antidepressant-attributed anti-COVID-19 activity was attributed to … Continue reading →

Posted in Uncategorized | Comments Off on Molecular Bases of Serotonin Reuptake Inhibitor Antidepressant-Attributed Effects in COVID-19